

Clinical Pharmacology & Therapeutics: Past, Present, and Future

SA Waldman¹ and A Terzic²

***Clinical Pharmacology & Therapeutics (CPT)*, the definitive and timely source for advances in human therapeutics, transcends the drug discovery, development, regulation, and utilization continuum to catalyze, evolve, and disseminate discipline-transformative knowledge. Prioritized themes and multidisciplinary content drive the science and practice of clinical pharmacology, offering a trusted point of reference. An authoritative herald across global communities, CPT is a timeless information vehicle at the vanguard of discovery, translation, and application ushering therapeutic innovation into modern healthcare.**

A decade into joining the editorial team of *Clinical Pharmacology & Therapeutics (CPT)*, we here reflect on the Journal's ongoing evolution. *CPT* is foremost an enduring asset of the American Society for Clinical Pharmacology and Therapeutics, and more broadly an authoritative source of knowledge in the dynamic discipline of clinical pharmacology and human therapeutics.¹ Recognized as a premier vehicle for disseminating new concepts, ideas, and information, *CPT* serves as a principle and trusted portal to the discipline.² It has steadily anchored a multidisciplinary field central to translational and applied clinical medicine, advancing human health by focusing on the nature, activity, efficacy, and regulatory analysis of therapeutics.³ Building on a platform of key values at the

core of clinical pharmacology and therapeutics, *CPT* has matured into a global forum at the center of diversified communities of practice driving discovery, development, regulation, and utilization of therapeutics, the DDRU continuum, in this evolving time of systems biology and precision therapeutics.² Indeed, as in past years, each of our thematic issues in 2016 underscores key advances, or emerging domains, within the field including therapeutic innovations,⁴ precision medicine,⁵ big data,⁶ therapeutic optimization,⁷ epigenetics,^{8,9} the microbiome,¹⁰ pregnancy and lactation,¹¹ thrombosis,¹² immune-oncology,¹³ rare diseases,¹⁴ transporters,¹⁵ and adaptive biomedical innovation.¹⁶

CPT has in fact expanded its utility, appeal, and relevance, underscored by a

¹Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; ²Center for Regenerative Medicine, Departments of Cardiovascular Diseases, Molecular Pharmacology and Experimental Therapeutics, and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA. Correspondence: SA Waldman (scott.waldman@jefferson.edu) or A Terzic (terzic.andre@mayo.edu)

doi:10.1002/cpt.592

25% increase in article downloads in 2016 compared to the previous year. As utilization has increased, the Journal continues to support a rigorous peer-review program, orchestrated by Associate Editors with deep domain expertise covering the landscape of clinical pharmacology and its many facets.¹ In that context, peer review seeks to identify manuscripts that describe new therapeutic paradigms, reveal novel mechanistic insights, define evolving regulatory strategies, or in other ways transform or expand the dimensions of practice in clinical pharmacology. The impact of the content of *CPT* can be appreciated by considering the breadth of its audience, with more than 2,000,000 online page views in the last 2 years. The high quality of papers published and their ability to influence the discipline is highlighted by the continued outstanding performance of the impact factor, which was at 7.268 in 2015. The consistency of impact maintains *CPT* as a top journal publishing original research articles in the category of pharmacology and pharmacy of the Institute for Scientific Information (ISI).

Beyond original research, *CPT* serves as an essential vehicle to expand the dimensionality of the discipline of clinical pharmacology for clinicians, drug developers, laboratory scientists, and regulators, across multinational communities of practice. The Journal highlights emerging scientific fields, developing therapeutic innovations, advances in the science of drug development, and evolving regulatory strategies that complement the application of new platform technologies, to keep our readership informed and current about the broad evolution of this highly vibrant discipline.^{17–19} Moreover, the Journal showcases current controversies in the field, highlights notable achievements by our members, and serves as a scholarly forum for discussion and debate that underscores the relevance of our discipline to societal issues around the globe.¹⁹

This has been accomplished, in part, by experimenting with innovative thematic content over the last 10 years which, in many ways, has evolved into a unique identity for the Journal. Established components that have garnered popularity with the readership include Commentaries²⁰ and Point-Counterpoint, which offer context for practice-changing science in original research articles or thoughtfully highlight ongoing controversies and debates in our discipline. Macroscopy²¹ continues to remind us that our discipline impacts, and is impacted by, the larger canvas of geopolitical, socioeconomic, and environmental issues that bind us in a global community. The latest innovations in molecular, clinical, and regulatory sciences are showcased in Opinion pieces, including Discovery,²² Translation,²³ and Development.^{24,25} Moreover, State of the Art²⁶ and Reviews²⁷ offer authoritative synthesized content, reflected by their high rate of citations, providing in-depth analysis of emerging trends in the practice of clinical pharmacology.

Beyond those established components, during the last 5 years we added new content to *CPT*, to continue the evolution of the journal and keep the readership ahead of advancing trends in the discipline. Innovation in precision medicine, with a particular focus on therapeutic selection reflecting the molecular fingerprints of pathobiology, is revolutionizing patient management. In turn, these advances have been driven by the dual engines of discovery and development, fed by the deconvolution of elemental biology coupled with technology platforms that are transforming medicine. To capture these developments for the readership, which span the continuum from discovery to application, we instituted an annual January issue dedicated to Therapeutic Innovations that are changing the practice of healthcare.^{28,29} Further, in recognition of the essential role that drug

development plays in the evolution of biological discoveries into human therapies, we have developed a strategic focus on Clinical Trials,^{30,31} the essential bridge between scientific and technical innovation and clinical translation and application. Moreover, it is clear that genetics and genomics have transformed our understanding of drug action, permitting the optimization of therapeutics for individuals and populations. One challenge in productively linking science and medicine generally, and in translating genomic discoveries in the laboratory to better therapies in patients specifically, is advancing experimental insights into clinical practice. In that regard, we have been privileged to collaborate with the Pharmacogenomics Research Network (PGRN), the Pharmacogenomics Knowledge Base (PharmGKB), and the Clinical Pharmacogenetics Implementation Consortium (CPIC)^{32–34} to disseminate practice guidelines that define how practitioners can use genetic and genomic information to best tailor therapies to individual patients.

As a discipline leader, *CPT* translates relevant progress in science and technology into innovations that maintain wellness and health and transform the management of disease. In an effort to keep readership on the advancing edge of the technological wave and maintain its relevance to careers in the discipline, we will embark on several new initiatives during the next stage of the Journal's evolution. We have heard the voices of the readership, which have underscored the importance of a greater focus on showcasing original research from our membership across diverse communities of practice. Thus, we are working with our Wiley publishing colleagues and ASCPT to create the ability and greater opportunities to publish a larger number of original research articles that span the DDRU continuum in each issue. In that context, we invite members of the Society, specifically, and the discipline overall to submit original

research for consideration by the Journal. Also, the popularity of CPICs, reflecting the importance of expertly curated information to translate innovation into practice, is driving our efforts to explore the possibility of collaborations with other organizations to produce practice guidelines advancing diagnosis and treatment. Further, we recognize the increasing contribution of investigators at the earliest stages of molecular discoveries to the discipline of clinical pharmacology and the development of innovations in diagnosis and treatment. Thus, we will expand the overall focus of the Journal to include original research at the earliest stages of the DDRU continuum. Moreover, the ASCPT publication portfolio has expanded with the addition of *Clinical and Translational Science*, and we are looking forward to increasing our interactions, along with *CPT: Pharmacometrics & Systems Pharmacology*, to maximize the synergies that these interrelated journals offer. With these combined efforts, *CPT* looks forward to expanding and enhancing the relevance of our content, disseminating transformative science, and catalyzing discussions about issues confronting the discipline that are essential to our highly diverse communities of practice.

CONFLICT OF INTEREST

The authors have no relevant disclosures.

ACKNOWLEDGMENTS

S.A.W. is the Samuel M.V. Hamilton Professor of Medicine of Thomas Jefferson University. A.T. is the Marriott Family Professor of Cardiovascular Research at the Mayo Clinic. This work was supported by grants from the National Institutes of Health (NIH) R01 (CA170533, CA206026), Targeted Diagnostic & Therapeutics, Inc., Marriott Foundation and Mayo Clinic.

© 2017 ASCPT

1. Waldman, S.A. & Terzic, A. Clinical Pharmacology & Therapeutics: the next five years. *Clin. Pharmacol. Ther.* **97**, 2–6 (2015).
2. Smith, B.P. & Huang, S.M. Novel approaches to address challenges in global drug development. *Clin. Pharmacol. Ther.* **97**, 196–199 (2015).

3. Waldman, S.A. & Terzic, A. Companion diagnostics at the intersection of personalized medicine and healthcare delivery. *Biomark. Med.* **9**, 1–3 (2015).
4. Waldman, S.A. & Terzic, A. Bioinnovation enterprise: an engine driving breakthrough therapies. *Clin. Pharmacol. Ther.* **99**, 8–13 (2016).
5. Pacanowski, M. & Huang, S.M. Precision medicine. *Clin. Pharmacol. Ther.* **99**, 124–129 (2016).
6. Waldman, S.A. & Terzic, A. Big data transforms discovery-utilization therapeutics continuum. *Clin. Pharmacol. Ther.* **99**, 250–254 (2016).
7. Vinks, A.A. Therapeutic optimization as part of the precision medicine paradigm. *Clin. Pharmacol. Ther.* **99**, 340–342 (2016).
8. Cascorbi, I. & Schwab, M. Epigenetics in drug response. *Clin. Pharmacol. Ther.* **99**, 468–470 (2016).
9. Ingelman-Sundberg, M. & Cascorbi, I. Pharmacogenomic or -epigenomic biomarkers in drug treatment: two sides of the same medal? *Clin. Pharmacol. Ther.* **99**, 478–480 (2016).
10. Philpott, D.J. & Piquette-Miller, M. The bugs within our body: the human microbiota. *Clin. Pharmacol. Ther.* **99**, 570–574 (2016).
11. Ito, S. Mother and child: medication use in pregnancy and lactation. *Clin. Pharmacol. Ther.* **100**, 8–11 (2016).
12. Hohl, R.J. Anticoagulants: major advances without clear consensus. *Clin. Pharmacol. Ther.* **100**, 116–118 (2016).
13. McCune, J.S. Immunotherapy to treat cancer. *Clin. Pharmacol. Ther.* **100**, 198–203 (2016).
14. Smith, B.P. Challenges and opportunities in rare disease drug development. *Clin. Pharmacol. Ther.* **100**, 312–314 (2016).
15. Govindarajan, R. & Sparreboom, A. Drug transporters: advances and opportunities. *Clin. Pharmacol. Ther.* **100**, 398–403 (2016).
16. Honig, P.K. & Hirsch, G. Adaptive biomedical innovation. *Clin. Pharmacol. Ther.* **100**, 574–578 (2016).
17. Birdwell, K.A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. *Clin. Pharmacol. Ther.* **98**, 19–24 (2015).
18. Cascorbi, I. Pharmacological treatment of pain: future trends and novel insights. *Clin. Pharmacol. Ther.* **97**, 104–108 (2015).
19. MacLeod, S.M., Greff, M., Knoppert, D.C., Ito, S. & Rieder, M.J. An international asset map of clinicians, educators, and researchers pursuing better medicine use in children: initial findings. *Clin. Pharmacol. Ther.* **101**, 274–280 (2017).
20. Musante, C.J., Ramanujan, S., Schmidt, B.J., Ghobrial, O.G., Lu, J. & Heatherington, A.C. Quantitative systems pharmacology: a case for disease models. *Clin. Pharmacol. Ther.* (2016) [Epub ahead of print].
21. Munos, B.H. Biomedical innovation: lessons from the past and perspectives for the future. *Clin. Pharmacol. Ther.* **100**, 588–590 (2016).
22. Vogel, K.R., Ainslie, G.R., Pearl, P.L. & Gibson, K.M. Aberrant mTOR signaling and disrupted autophagy: the missing link in potential vigabatrin-associated ocular toxicity? *Clin. Pharmacol. Ther.* (2016) [Epub ahead of print].
23. Allickson, J.G. Emerging translation of regenerative therapies. *Clin. Pharmacol. Ther.* **101**, 28–30 (2017).
24. Pasqualini, F.S., Emmert, M.Y., Parker, K.K. & Hoerstrup, S.P. Organ chips: quality assurance systems in regenerative medicine. *Clin. Pharmacol. Ther.* **101**, 31–34 (2017).
25. Yang, Y.S., Marder, S.R. & Green, M.F. Repurposing drugs for cognition in schizophrenia. *Clin. Pharmacol. Ther.* **101**, 191–193 (2017).
26. Roberts, A.W. & Huang, D.C. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in CLL and related B cell malignancies. *Clin. Pharmacol. Ther.* **101**, 89–98 (2017).
27. Cocucci, E., Kim, J.Y., Bai, Y. & Pabla, N. Role of passive diffusion, transporters, and membrane trafficking-mediated processes in cellular drug transport. *Clin. Pharmacol. Ther.* **101**, 121–129 (2017).
28. George, G., Vaid, U. & Summer, R. Therapeutic advances in idiopathic pulmonary fibrosis. *Clin. Pharmacol. Ther.* **99**, 30–32 (2016).
29. Subbotina, E., Koganti, S.R., Hodgson-Zingman, D.M. & Zingman, L.V. Morpholino-driven gene editing: a new horizon for disease treatment and prevention. *Clin. Pharmacol. Ther.* **99**, 21–25 (2016).
30. Burmeister Getz, E., Carroll, K.J., Jones, B. & Benet, L.Z. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: a dry powder inhaler randomized clinical trial. *Clin. Pharmacol. Ther.* **100**, 223–231 (2016).
31. Getz, E.B., Carroll, K.J., Mielke, J., Benet, L.Z. & Jones, B. Between-batch pharmacokinetic variability inflates type I error rate in conventional bioequivalence trials: a randomized Advair Diskus(R) clinical trial. *Clin. Pharmacol. Ther.* **101**, 331–340 (2017).
32. Gammal, R.S. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. *Clin. Pharmacol. Ther.* **99**, 363–369 (2016).
33. Hicks, J.K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin. Pharmacol. Ther.* **98**, 127–134 (2015).
34. Saito, Y. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. *Clin. Pharmacol. Ther.* **99**, 36–37 (2016).